From: Low-dose aspirin and survival from lung cancer: a population-based cohort study
Medication usage after diagnosis | Cancer-specific deaths | All-cause mortality | All patients | Person years | Cancer-specific mortality | All-cause mortality | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unadjusted | P | Adjusteda | P | Unadjusted | P | Adjusteda | P | |||||||||
HR | 95 % CI | HR | 95 % CI | HR | 95 % CI | HR | 95 % CI | |||||||||
Number of patients | [n = 13,433] | [n = 13,388] | [n = 13,433] | [n = 13,388] | ||||||||||||
Aspirin non-user | 7,577 | 8,369 | 9,564 | 9,154 | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | 1.00 | Referent | ||||
Aspirin user | 3,055 | 3,468 | 3,869 | 3,331 | 1.07 | 1.02, 1.11 | <0.01 | 1.00 | 0.95, 1.05 | 0.91 | 1.10 | 1.05, 1.14 | <0.001 | 1.01 | 0.96, 1.06 | 0.77 |
Aspirin non-user | 7,577 | 8,369 | 9,564 | 9,154 | 1.00 | Referent | 1.00 | Referent | 1.00 | 1.00 | 1.00 | Referent | ||||
Aspirin user 1 to 11 prescriptions | 2,367 | 2,690 | 2,998 | 2,608 | 1.06 | 1.01, 1.11 | 0.02 | 0.99 | 0.94, 1.04 | 0.75 | 1.09 | 1.04, 1.14 | <0.001 | 1.00 | 0.95, 1.05 | 0.90 |
Aspirin user ≥ 12 prescriptions | 688 | 778 | 871 | 723 | 1.09 | 1.01, 1.18 | 0.03 | 1.02 | 0.94, 1.11 | 0.64 | 1.11 | 1.04, 1.20 | <0.01 | 1.02 | 0.95, 1.11 | 0.57 |
Aspirin non-user | 7,577 | 8,369 | 9,564 | 9,154 | 1.00 | Referent | 1.00 | Referent | 1.00 | 1.00 | 1.00 | Referent | ||||
Aspirin user 1–365 tablets | 2,214 | 2,508 | 2,804 | 2,436 | 1.06 | 1.01, 1.12 | 0.01 | 1.00 | 0.95, 1.06 | 0.97 | 1.09 | 1.04, 1.14 | <0.001 | 1.01 | 0.96, 1.06 | 0.70 |
Aspirin user ≥366 tablets | 841 | 960 | 1,065 | 895 | 1.07 | 1.00, 1.15 | 0.06 | 0.98 | 0.91, 1.06 | 0.70 | 1.11 | 1.04, 1.18 | <0.01 | 1.00 | 0.93, 1.07 | 0.97 |